During the 28 months of the project, according to the mechanical scale-up and optimisation of the HYDROBLOOD process (WP1), the HYDROBLOOD demonstrator plant has been fully designed (P&ID development and optimisation, commercial equipment selection, taylor made equipment design, etc.), and all the commercial and taylor made components have been ordered/manufactured. During the process optimisation phase, several modifications from the initial design have been integrated in the industrial scale processing plant, especially within the hygienic blood processing line, in order to optimise the production rate and minimise costs, while maintaining the quality of the final product obtained. In parallel with this, the control system and electrical architecture of the demonstrator plant (WP2) have been fully developed (architecture definition, SCADA development, PLC code implementation, electrical diagrams, 2D layout of electric cabinet, and selection of components). After that, all the electric and automation components have been purchased, and electrical/control cabinets have been set-up and wired. An on-line monitoring platform to monitor different HYDROBLOOD processing plants has been also designed and developed within this WP, and deployed on TALLERES AZUARA’s server. Once the demonstrator plant design has been finished, several legal and certification actions have been conducted (WP3). All the legal allowances for HYDROBLOOD processing plant construction and operation have been obtained from relevant administration. Moreover, all the certification and homologation requirements for the HYDROBLOOD processing plant and the Decoloured Hydrolysed Protein (DHP) have been assessed, and technical documentation presented to relevant administration when needed. In the last stage of project execution, the HYDROBLOOD DEMO plant has been fully commissioned (WP4) within MAFRICA slaughterhouse’s facilities, and final validation and process optimisations have been carried out. Several batches of protein have been then obtained and analysed in laboratory, with very positive results. During the whole project execution, commercialisation and communication (WP5), as well as management (WP6) activities, have been conducted, such as: Brand creation strategy definition, commercialisation strategy validation, visits to potential clients, assistance to trade missions and trade fairs, Business Plan update, market assessment update, social media accounts creation for the dissemination of the HYDROBLOOD project (with up to date information published regularly), promotional material creation for the promotion of our invention, Freedom to operate through the HYDROBLOOD process IPR validation, among others.
